172 related articles for article (PubMed ID: 35810555)
1. Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial.
Ligorio F; Fucà G; Provenzano L; Lobefaro R; Zanenga L; Vingiani A; Belfiore A; Lorenzoni A; Alessi A; Pruneri G; de Braud F; Vernieri C
Eur J Cancer; 2022 Sep; 172():300-310. PubMed ID: 35810555
[TBL] [Abstract][Full Text] [Related]
2. Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
Ligorio F; Lobefaro R; Fucà G; Provenzano L; Zanenga L; Nasca V; Sposetti C; Salvadori G; Ficchì A; Franza A; Martinetti A; Sottotetti E; Formisano B; Depretto C; Scaperrotta G; Belfiore A; Vingiani A; Ferraris C; Pruneri G; de Braud F; Vernieri C
Int J Cancer; 2024 Jan; 154(1):114-123. PubMed ID: 37615485
[TBL] [Abstract][Full Text] [Related]
3. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.
Vernieri C; Fucà G; Ligorio F; Huber V; Vingiani A; Iannelli F; Raimondi A; Rinchai D; Frigè G; Belfiore A; Lalli L; Chiodoni C; Cancila V; Zanardi F; Ajazi A; Cortellino S; Vallacchi V; Squarcina P; Cova A; Pesce S; Frati P; Mall R; Corsetto PA; Rizzo AM; Ferraris C; Folli S; Garassino MC; Capri G; Bianchi G; Colombo MP; Minucci S; Foiani M; Longo VD; Apolone G; Torri V; Pruneri G; Bedognetti D; Rivoltini L; de Braud F
Cancer Discov; 2022 Jan; 12(1):90-107. PubMed ID: 34789537
[TBL] [Abstract][Full Text] [Related]
4. Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer.
Ligorio F; Provenzano L; Vernieri C
Curr Opin Oncol; 2023 Nov; 35(6):491-499. PubMed ID: 37621169
[TBL] [Abstract][Full Text] [Related]
5. Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
Vernieri C; Signorelli D; Galli G; Ganzinelli M; Moro M; Fabbri A; Tamborini E; Marabese M; Caiola E; Broggini M; Hollander L; Gallucci R; Vandoni G; Gavazzi C; Triulzi T; Colombo MP; Rizzo AM; Corsetto PA; Pruneri G; de Braud F; Sozzi G; Torri V; Garassino MC
Clin Lung Cancer; 2019 May; 20(3):e413-e417. PubMed ID: 30617039
[TBL] [Abstract][Full Text] [Related]
6. Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment.
Valdemarin F; Caffa I; Persia A; Cremonini AL; Ferrando L; Tagliafico L; Tagliafico A; Guijarro A; Carbone F; Ministrini S; Bertolotto M; Becherini P; Bonfiglio T; Giannotti C; Khalifa A; Ghanem M; Cea M; Sucameli M; Murialdo R; Barbero V; Gradaschi R; Bruzzone F; Borgarelli C; Lambertini M; Vernieri C; Zoppoli G; Longo VD; Montecucco F; Sukkar SG; Nencioni A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439167
[TBL] [Abstract][Full Text] [Related]
7. Fasting-Mimicking Diet Inhibits Autophagy and Synergizes with Chemotherapy to Promote T-Cell-Dependent Leukemia-Free Survival.
Buono R; Tucci J; Cutri R; Guidi N; Mangul S; Raucci F; Pellegrini M; Mittelman SD; Longo VD
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136414
[TBL] [Abstract][Full Text] [Related]
8. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
9. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
10. Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial.
Lugtenberg RT; de Groot S; Kaptein AA; Fischer MJ; Kranenbarg EM; Carpentier MD; Cohen D; de Graaf H; Heijns JB; Portielje JEA; van de Wouw AJ; Imholz ALT; Kessels LW; Vrijaldenhoven S; Baars A; Fiocco M; van der Hoeven JJM; Gelderblom H; Longo VD; Pijl H; Kroep JR;
Breast Cancer Res Treat; 2021 Feb; 185(3):741-758. PubMed ID: 33179154
[TBL] [Abstract][Full Text] [Related]
11. Antitumour antibiotic containing regimens for metastatic breast cancer.
Lord S; Ghersi D; Gattellari M; Wortley S; Wilcken N; Simes J
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD003367. PubMed ID: 15495049
[TBL] [Abstract][Full Text] [Related]
12. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
13. Fasting and cancer: molecular mechanisms and clinical application.
Nencioni A; Caffa I; Cortellino S; Longo VD
Nat Rev Cancer; 2018 Nov; 18(11):707-719. PubMed ID: 30327499
[TBL] [Abstract][Full Text] [Related]
14. Fasting-Mimicking Diet Drives Antitumor Immunity against Colorectal Cancer by Reducing IgA-Producing Cells.
Zhong Z; Zhang H; Nan K; Zhong J; Wu Q; Lu L; Yue Y; Zhang Z; Guo M; Wang Z; Xia J; Xing Y; Fu Y; Yu B; Zhou W; Sun X; Shen Y; Chen W; Zhang J; Zhang J; Ma D; Chu Y; Liu R; Miao C
Cancer Res; 2023 Nov; 83(21):3529-3543. PubMed ID: 37602826
[TBL] [Abstract][Full Text] [Related]
15. Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia.
Raucci F; Vernieri C; Di Tano M; Ligorio F; Blaževitš O; Lazzeri S; Shmahala A; Fragale G; Salvadori G; Varano G; Casola S; Buono R; Visco E; de Braud F; Longo VD
Cancer Res; 2024 Apr; 84(7):1133-1148. PubMed ID: 38241703
[TBL] [Abstract][Full Text] [Related]
16. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).
Lau SP; van 't Land FR; van der Burg SH; Homs MYV; Lolkema MP; Aerts JGJV; van Eijck CHJ
BMJ Open; 2022 Jun; 12(6):e060431. PubMed ID: 35710239
[TBL] [Abstract][Full Text] [Related]
17. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial.
de Groot S; Lugtenberg RT; Cohen D; Welters MJP; Ehsan I; Vreeswijk MPG; Smit VTHBM; de Graaf H; Heijns JB; Portielje JEA; van de Wouw AJ; Imholz ALT; Kessels LW; Vrijaldenhoven S; Baars A; Kranenbarg EM; Carpentier MD; Putter H; van der Hoeven JJM; Nortier JWR; Longo VD; Pijl H; Kroep JR;
Nat Commun; 2020 Jun; 11(1):3083. PubMed ID: 32576828
[TBL] [Abstract][Full Text] [Related]
18. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
19. Fasting and fasting mimicking diets in cancer prevention and therapy.
Blaževitš O; Di Tano M; Longo VD
Trends Cancer; 2023 Mar; 9(3):212-222. PubMed ID: 36646607
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
